Addressing Disparities in Alcohol Use Disorder Treatment: A Call to Action

Dr. Kranzler is a member of advisory boards for Altimmune, Inc., Clearmind Medicine, Dicerna Pharmaceuticals, Enthion Pharmaceuticals, Lilly Pharmaceuticals, and Sophrosyne Pharmaceuticals; a consultant to Altimmune, Inc. and Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. Dr. Vicker-Smith reports no financial relationships with commercial interests.